Laurus Labs developing third-line HIV treatment for children

14 Sep 2021 Evaluate

Laurus Labs is developing a third-line HIV treatment, darunavir boosted with ritonavir (DRV/r), for children. The development is under way based on an agreement inked in June 2021 by the Hyderabad-based company, Unitaid and the Clinton Health Access Initiative (CHAI).

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1038.70 1.40 (0.13%)
11-Mar-2026 15:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.45
Dr. Reddys Lab 1326.10
Cipla 1328.50
Zydus Lifesciences 920.50
Lupin 2340.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×